The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion

Go back to The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7 Billion

SVB Leerink Downgrades The Medicines Company (MDCO) to Market Perform

November 25, 2019 8:10 PM EST

SVB Leerink analyst Joseph Schwartz downgraded The Medicines Company (NASDAQ: MDCO) from Outperform to Market Perform with a price target of $85.00 (from $78.00).

For an analyst ratings summary and ratings history on The Medicines Company... More